CompletedNCT00314821
Ropinirole for depression in bipolarity
About this title
Ropinirole in the Treatment of Bipolar Depression
Read the official source — NCT00314821Medication studyAges 18–64United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Atlanta and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: September 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Cambridge Health Alliance
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00314821
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Atlanta · Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cambridge Health Alliance.
Did this study involve medication?
Yes. The study involved medication, including ropinirole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
